Abbott (ABT) Receives Japan MHLW Approval of Absorb Heart Stent
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Abbott (NYSE: ABT) announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Japan with coronary artery disease.
Absorb is the only fully dissolving heart stent approved in Japan for the treatment of heart disease, one of the leading causes of death in Japan and worldwide. An estimated 1.73 million2 people in Japan (population: 127 million) have heart disease, and approximately 71.7 thousand3 people die each year from coronary artery disease, making it the secondary leading cause of death in the country annually. Worldwide, more than 7.4 million people die of heart disease each year.4
"Absorb has the potential to address the unsolved challenges of managing coronary artery disease with conventional drug eluting metallic stents," said Prof. Takeshi Kimura, M.D., Ph.D., director of cardiovascular medicine at Kyoto University Hospital in Japan and the principal investigator of ABSORB JAPAN, the clinical study that led to the MHLW's approval of the device. "Our research, which involved 400 patients at 38 Japanese sites, shows that this fully dissolving stent delivered comparable results to the best-in-class Abbott XIENCE® metallic drug-eluting stent on clinically important measures of safety and efficacy."
Japan ranks as the second-largest single-country market for advanced medical technology behind the United States, where the U.S. Food and Drug Administration (FDA) approved Absorb in July 2016.
While stents are traditionally made of metal, Abbott's Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely5 in approximately three years, once it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that may cause future blockages.
"We're very excited to bring the promise of Absorb to patients in Japan," said Deepak Nath, Ph.D., senior vice president, vascular, Abbott. "We believe the Absorb bioresorbable stent can help people live better, healthier lives without the concern of a having a metal implant."
Abbott's Absorb stent, sold commercially as the Absorb GT1 Bioresorbable Vascular Scaffold (BVS) system, has been used to treat more than 150,0001 people in more than 100 countries around the world. Absorb was recently approved in the United States and Canada.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm (QCOM) Responds to FTC Antitrust Charges
- Caesars Entertainment (CZR) Announces Confirmation of CEOC's Plan of Reorganization
- Big 5 Sporting Goods (BGFV) Q4 Comps Rise 3.1%; Guides Q4 Above the Street
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!